Uncertainty surrounds cancer vaccine review at FDA.

The article discusses the cancer drug DCVax-Brain and its approval process in Switzerland and the United States. The article describes how the Swiss Institute of Public Health declared that it would allow the importing and exporting of the drug even though it has not been approved. The United States Food and Drug Administration has delayed the development of the drug in order to ensure proper execution of clinical outcomes. Details are provided regarding the drug's use as a vaccine consisting in dendritic cells pulsed with antigens derived from a tumor cell lysate from a resected gioblastoma. Also discussed are the cancer drugs Provenge, Junovan, and MyVax.